Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK8 | P49336 | 4/20 | 0.46 |
| ▸ | CCNC | P24863 | 2/20 | 0.46 |
| ▸ | GAK | O14976 | 2/20 | 0.44 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.44 |
| ▸ | COQ8A | Q8NI60 | 2/20 | 0.44 |
| ▸ | NLK | Q9UBE8 | 2/20 | 0.44 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.43 |
| ▸ | PDE5A | O76074 | 1/20 | 0.39 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.38 |
| ▸ | CDKN1A | P38936 | 1/20 | 0.37 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.37 |
| ▸ | RAF1 | P04049 | 1/20 | 0.37 |
| ▸ | BRAF | P15056 | 1/20 | 0.37 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.36 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.36 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.36 |
| ▸ | GSK3A | P49840 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3400822 | 0.83 | SLC22A12 (0.46) | CDK8CCNCGAKRIPK2COQ8A | |
| SCHEMBL16289814 | 0.83 | CDK8 (0.48) | CDK8CCNCGAKRIPK2COQ8A | |
| SCHEMBL30369707 | 0.76 | PDE5A (0.49) | CDK8CCNCGAKRIPK2COQ8A | |
| SCHEMBL981901 | 0.76 | CDK8 (0.51) | CDK8CCNCGAKRIPK2COQ8A | |
| SCHEMBL633785 | 0.76 | CDK8 (0.48) | CDK8CCNCGAKRIPK2COQ8A | |
| SCHEMBL23625624 | 0.76 | CDK8 (0.48) | CDK8CCNCGAKRIPK2COQ8A | |
| SCHEMBL730084 | 0.76 | PDE5A (0.49) | CDK8CCNCGAKRIPK2COQ8A | |
| SCHEMBL29843629 | 0.76 | SLC22A12 (0.51) | CDK8CCNCGAKRIPK2COQ8A | |
| SCHEMBL29843782 | 0.76 | CDK8 (0.48) | CDK8CCNCGAKRIPK2COQ8A | |
| SCHEMBL3582506 | 0.76 | NR4A2 (0.56) | CDK8CCNCGAKRIPK2COQ8A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7498326-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2009-03-03 | — | — | US | disclosed |
| WO-2007016610-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007016610-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2007-02-08 | — | — | WO | disclosed |
| US-20060058287-A1 | Gramnegative and Grampositive bacterial infections; substituted Piperidine derivatives specially optionally substituted pyrido [3,2, -b][1,4] thiazin-yl; 6-({(3R,4S)-3-Fluoro-1-[(R)-2-hydroxy-2-(2-methoxy-quinolin-8-yl)-ethyl]-piperidin-4-ylamino }-methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one; nontoxic | GLAXO GROUP LIMITED (GB) | 2006-03-16 | — | — | US | disclosed |
| EP-1583537-A3 | PIPERIDINE COMPOUNDS AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2005-12-14 | — | — | EP | disclosed |
| EP-1583537-A2 | PIPERIDINE COMPOUNDS AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2005-10-12 | — | — | EP | disclosed |
| WO-2004002490-A2 | PIPERIDINE COMPOUNDS AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2004-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058287-A1 | Gramnegative and Grampositive bacterial infections; substituted Piperidine derivatives specially optionally substituted pyrido [3,2, -b][1,4] thiazin-yl; 6-({(3R,4S)-3-Fluoro-1-[(R)-2-hydroxy-2-(2-methoxy-quinolin-8-yl)-ethyl]-piperidin-4-ylamino }-methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one; nontoxic | TLR1, TLR2, TLR6 | CDK8 2594/4885CCNC 3694/4885GAK 1150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.